1475 related articles for article (PubMed ID: 8746340)
1. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
[TBL] [Abstract][Full Text] [Related]
2. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
3. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
4. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.
He J; Olson JJ; James CD
Cancer Res; 1995 Nov; 55(21):4833-6. PubMed ID: 7585516
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
6. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
8. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
9. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
10. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
12. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
Nobori T; Miura K; Wu DJ; Lois A; Takabayashi K; Carson DA
Nature; 1994 Apr; 368(6473):753-6. PubMed ID: 8152487
[TBL] [Abstract][Full Text] [Related]
13. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond A; Brent R
Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
15. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
16. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.
Tam SW; Shay JW; Pagano M
Cancer Res; 1994 Nov; 54(22):5816-20. PubMed ID: 7954407
[TBL] [Abstract][Full Text] [Related]
17. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
19. 5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
Della Ragione F; Russo G; Oliva A; Mastropietro S; Mancini A; Borrelli A; Casero RA; Iolascon A; Zappia V
Oncogene; 1995 Mar; 10(5):827-33. PubMed ID: 7898924
[TBL] [Abstract][Full Text] [Related]
20. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
Otterson GA; Kratzke RA; Coxon A; Kim YW; Kaye FJ
Oncogene; 1994 Nov; 9(11):3375-8. PubMed ID: 7936665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
